Patrick M ONeil
Overview
Explore the profile of Patrick M ONeil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1982
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ard J, Ryan D, ONeil P, Kushner R, Wyatt H, Bays H, et al.
Obesity (Silver Spring)
. 2025 Feb;
33(3):500-511.
PMID: 39904726
Objective: The objective of this study was to investigate the efficacy and safety of the Epitomee capsule versus placebo as an adjunct to high-intensity lifestyle intervention in participants with overweight...
2.
Fowler L, Fernandez J, ONeil P, Parcha V, Arora P, Shetty N, et al.
Arch Med Res
. 2024 Nov;
56(3):103128.
PMID: 39579522
Background: Type 2 diabetes (T2D) risk is higher among non-Hispanic black (NHB) and Hispanic individuals, for reasons that are unclear. Aims: With this cross-sectional study, we tested the hypothesis that...
3.
Smith C, ONeil P
Subst Use Misuse
. 2024 May;
59(10):1481-1487.
PMID: 38803011
Tobacco use and obesity are leading causes of preventable death in the U.S. E-cigarette use is on the rise; however, obesity prevalence among e-cigarette users is unknown. The present study...
4.
Kyrillos J, ONeil P, Wharton S
Postgrad Med
. 2023 Jan;
134(sup1):1-4.
PMID: 36691310
No abstract available.
5.
ONeil P, Rubino D
Postgrad Med
. 2023 Jan;
134(sup1):28-36.
PMID: 36691307
Obesity negatively impacts patients' health-related quality of life (QOL) and is associated with a range of complications such as type 2 diabetes (T2D), cardiovascular disease, and sleep apnea, alongside decreased...
6.
7.
Rubino D, Greenway F, Khalid U, ONeil P, Rosenstock J, Sorrig R, et al.
JAMA
. 2022 Jan;
327(2):138-150.
PMID: 35015037
Importance: Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like peptide-1 analogues available for weight management. Objective: To compare the efficacy and adverse event profiles of once-weekly subcutaneous semaglutide,...
8.
El Hajj E, El Hajj M, Sykes B, Lamicq M, Zile M, Malcolm R, et al.
J Am Heart Assoc
. 2021 Oct;
10(21):e022930.
PMID: 34713711
Background Obesity is associated with heart failure with preserved ejection fraction (HFpEF). Weight loss can improve exercise capacity in HFpEF. However, previously reported methods of weight loss are impractical for...
9.
Hales S, Schulte E, Turner T, Malcolm R, Wojtanowski A, Rethorst C, et al.
Transl Behav Med
. 2021 Sep;
11(12):2091-2098.
PMID: 34479369
WW is a validated behavioral weight management program that encourages healthy habits. WW developed a method of personalizing the SmartPoints® budget depending on dietary and lifestyle preferences, and participants were...
10.
Wadden T, Bailey T, Billings L, Davies M, Frias J, Koroleva A, et al.
JAMA
. 2021 Feb;
325(14):1403-1413.
PMID: 33625476
Importance: Weight loss improves cardiometabolic risk factors in people with overweight or obesity. Intensive lifestyle intervention and pharmacotherapy are the most effective noninvasive weight loss approaches. Objective: To compare the...